PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

New AI-Powered Research Library from ISR Market Research to Streamline Pharma Decision-Making 

Specialist pharmaceutical outsourcing research firm invests in new ways to access market intelligence as evolving buyer expectations and industry risks increase the complexity of commercial decision-making

Cary, North Carolina, 28 October 2026 – ISR Market Research (ISR), a ramarketing Group company is developing an AI-enabled interface for its specialist pharmaceutical outsourcing research library, to give pharma companies access to the latest intel to inform crucial commercial decisions and evaluate potential partners. 

With a launch date targeted for early 2027, this development aims to make ISR’s extensive portfolio of syndicated benchmarking and market dynamics research easier to access and navigate, helping organizations find relevant information more efficiently and make confident commercial decisions.

The investment comes as pharmaceutical and biotech companies navigate increasingly complex outsourcing decisions, with geopolitical uncertainty, supply chain risks and changing buyer expectations influencing how organizations evaluate and select service providers.

Kate Hammeke, CEO of ISR Market Research, said: “The questions businesses are asking about pharmaceutical outsourcing are becoming more complex. They’re having to consider a broader range of risks, while also understanding how buyer expectations and supplier relationships are evolving.

“We’ve spent more than 15 years building research that helps organizations navigate these decisions.

Developing new ways to access that intelligence is a natural next step, allowing us to build on the strength of our research and make it easier for customers to find the information that matters to them.”

According to ISR, traditional supplier selection criteria such as quality, regulatory compliance, pricing and delivery remain essential, but are increasingly regarded as baseline expectations rather than competitive differentiators.

Factors including communication, responsiveness and the ability to anticipate challenges are becoming more important as buyers seek suppliers capable of supporting them through an increasingly uncertain operating environment.

“Quality, on-time delivery and a strong regulatory track record used to be meaningful selling points. Today, they’re increasingly the expectation,” Hammeke explained.

“What becomes more important is how those suppliers work with their customers. Are they responsive? Do they communicate effectively? Can they identify potential problems early and help address them? Those are increasingly important factors in building the trust that successful outsourcing relationships depend on.”

ISR’s syndicated benchmarking studies and custom research help organizations understand these changing priorities by examining buyer expectations, supplier perceptions, competitive dynamics and customer experiences.

The initiative forms part of ISR’s next stage of growth following its acquisition by the ramarketing Group earlier in 2026. The company has also unveiled a refreshed brand identity and website, providing a clearer platform for its research offering and specialist expertise.

As part of the Group, ISR’s market research capabilities can also be complemented by ramarketing’s expertise in commercial strategy, positioning and marketing activation, helping organizations connect industry evidence with broader commercial decision-making.

Yasmin Davoodi, CCO, ramarketing Group, said: “ISR has built a strong reputation for its specialist research and understanding of the pharmaceutical outsourcing industry. Our focus is on building on that expertise and creating new opportunities for organizations to access and apply it.

“The development of the AI-enabled library, alongside ISR’s refreshed brand and website, reflects our ambition to strengthen how specialist market intelligence supports commercial decision-making across the industry.”

Visit the refreshed ISR Market Research website at www.isrreports.com.

About ISR Market Research

ISR Market Research is a specialist provider of primary market research focused on pharmaceutical outsourcing and drug development markets. Through syndicated benchmarking reports, market dynamics research and custom studies, ISR helps pharmaceutical and biotech organizations and their service providers better understand their markets, customers and competitors. ISR is part of the ramarketing Group.

www.isrreports.com

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026